Compare Marsh & McLennan Companies, Inc. (MRSH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Novavax Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $84.39B), while Novavax Inc trades at $9.86 (market cap $1.62B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 52.1× Novavax Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MRSH | NVAX | |
|---|---|---|
Market Cap | $84.39B | $1.62B |
Sector | Financials | Health |
52-Week High | $207.02 | $11.19 |
52-Week Low | $157.32 | $6.22 |
Enterprise Value | $105.07B | $1.20B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The company shows solid fundamentals with revenue growth to $26.98B in 2025 and consistent earnings beats. Analyst consensus is a Buy with a $208.63 price target, though sentiment is mixed with 66.7% Hold ratings. Recent news highlights expansion in cyber protection services and insights on healthcare cost trends.
The outlook remains positive given strong profitability and strategic initiatives, but risks include economic sensitivity and competitive pressures. The stock offers upside to the consensus target, supported by institutional interest and stable cash flows, though high valuation multiples warrant caution amid market volatility.
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
